- Home
- OCUL
as 03-14-2025 4:00pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.2B | IPO Year: | 2014 |
| Target Price: | $16.13 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.06 - $11.78 | Next Earning Date: | 03-03-2025 |
| Revenue: | $63,723,000 | Revenue Growth: | 9.03% |
| Revenue Growth (this year): | 14.02% | Revenue Growth (next year): | 15.47% |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nayak Sanjay | OCUL | Chief Strategy Officer | Feb 24 '25 | Sell | $6.84 | 1,895 | $12,961.80 | 283,485 | |
| Dugel Pravin | OCUL | See Remarks | Feb 24 '25 | Sell | $6.87 | 21,475 | $147,533.25 | 3,520,318 | |
| Kaiser Peter | OCUL | Chief Development Officer | Feb 24 '25 | Sell | $6.87 | 3,009 | $20,671.83 | 210,078 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | Feb 24 '25 | Sell | $6.87 | 3,061 | $21,029.07 | 265,998 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
Why Ocular Therapeutix Was Bumping Higher This Week
Benzinga
5 days ago
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
MT Newswires
5 days ago
Needham Initiates Ocular Therapeutix at Buy With $15 Price Target
GlobeNewswire
9 days ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
12 days ago
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...
Thomson Reuters StreetEvents
12 days ago
Q4 2024 Ocular Therapeutix Inc Earnings Call
Zacks
13 days ago
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
MT Newswires
13 days ago
Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises
Compare OCUL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.